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Abstract. Pro197Leu polymorphism of the gene GPX 1 has been
studied in 102 patients with MS and 97 healthy individuals. Disor-
ders of genotype frequencies distribution comparing with the control
group at the expense of the reduction of Pro/Pro genotype frequency
have been found in the main group (ð < 0,05). Assessment of the
relative risk was carried by odds ratio (OR) magnitude. The OR
calculation showed the growth of risk of GPX 1 activity disorder in
patients with Pro/Leu and Leu/Leu variants of polymorphism
comparing with homozygous for the Pro-allele at 4,7 and 6,9 times
respectively (ð < 0,05). Individuals with Leu/Leu genotype had
significantly higher level of VEGF and endothelial desquamation
intensity as compared with the persons with Pro/Pro genotype (ð <
0,05). Consequently, Pro-allele has protective properties, it means
that presence of these allele in genotype reduses risk of glutathione
peroxidase activity decreasing. In Leu-allele carriers, activity of GPX
1 decreases, free radicals accumulate, that cause lipid peroxidation
and activation of transcription factors, followed by increasing
expression of cytokines, which are also directly affect the endo-
thelium.
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Introduction
Cytoplasmic glutathione peroxidase (GPX 1) is
one of the selenoenzymes important for the organism
functioning, present in all tissues of the human body,
which takes part in detoxication of hydrogen
peroxide and products of lipid peroxidation, as
catalyzes the interaction of redused glutathione with
these substances [4, 5, 9, 10]. It is known that nume-
rous pathologic processes in the organism develop in
concequence of disorders in the mechanisms of
antioxidant protection. Specially, in patients with
insulin resistance accompanied by hyperglycemia and
increased production of cytokines there arises
oxidative stress. The accumulation of free radicals
activates factors of transcription such as nuclear
factor kappa-light-chain-enhancer of activated B cells
(NF-kb), which initiate the process of proinflam-
matory cytokines release [8]. The growth of free
radicals results in lipid peroxidation of cellular
membranes, causes atherosclerosis and endothelial
dysfunction [11].
We studied single nucleotide polymorphism of the
gene GPX 1 for going into the question of the de-
pendence of these processes upon the disorders of
redox homeostasis. The human gene GPX 1 is loca-
lized in 3p21 chromosome and consists of two exons.
Several single nucleotide polymorphism variants of
this gene are known, but the Pro197Leu poly-
morphism has been under our study, at which in the
position 593 the amino acid cytosine (C) is replaced
by thymine (T) (C593T), resulting in substitution of
the amino acid proline for leucine in the 197 codon.
This mutation refers to missense - functional poly-
morphisms. Pro-allele is "wild", while Leu- is a "mu-
tant" allele. The presence of Leu-allele causes dep-
ression of GPX 1 sensibility to stimulating factors [6].
However, the dependence of functional state of
endothelium parameters on Pro197Leu poly-
morphism of the GPX 1 gene against a background
of metabolic syndrome (MS) remains unstudied.
The aim of the study. To investigate the depen-
dence of functional state of endothelium parameters
on Pro197Leu polymorphism of the GPX 1 gene
against a background of metabolic syndrome.
Material and methods
Pro197Leu polymorphism of the gene GPX 1
have been studied in 102 patients with MS and 97
healthy individuals by isolation of genomic DNA
from peripheral blood leukocytes, and then
amplification of the polymorphic area in the state of
polymerase chain reaction (PCR) was performed on
the programmed PCR thermal cyclers "Amply-4L"
("Biocom", Ðîñ³ÿ) at individual temperature response.
Reagents "ÄÍÊ-ñîðá-Â" variant 100 (ÔÃÓÍ
ÖÍÈÈÝ, Ðîñ³ÿ) were used for DNA isolation from
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lymphocytes according to instructions. PCR samples
were prepared by means of the set "ÀìïëèÑåíñ-
200-1" (ÔÃÓÍ ÖÍÈÈÝ, Ðîñ³ÿ). Products of PCR
were separated using electrophoresis in 3% agarose
gel in the presence of tetraborate buffer, concent-
rated with ethidium bromide. Fragments were
visualized by transilyuminator in the presence of a
marker of molecular mass 100-1000 bð ("Fer-
mentasR", USA).
Pearson's criterion (χ 2) was used to estimate the
correspondence of the genotype  frequencies under
study to theoretically expected distribution at Hardy-
Weinberg's equation. Odds ratio (OR) with deter-
mination of 95% confidence interval (CI) was
calculated with the aim to establish the association of
polymorphic variant of the gene with a pathological
phenotype.
The diagnosis of MS was established according to
criteria of the International Diabetes Federation
(IDF) [2].
Endothelial function indices were investigated in
102 patients, 20 healthy individuals made control
group. The vascular endothelial growth factor
(VEGF) level was established by immunoassay me-
thod using a set of firm "Vector-Best". The number
of circulating desquamated endothelial cells was
calculated by Hladovec J. method in Petrishchev
N.N. et al. modification [3].
Statistical analysis of the obtained data was
carried out using the Student's t-test and Pearson's
rank correlation coefficient by means of the software
package Statistica 6.0 for Windows. The difference
was considered reliable at p < 0,05.
Results and discussion
When assessing the distribution of genotype
frequencies of the gene GPX 1, it has been found
that in the group of patients with MS threre takes
place a significant reduction of the frequency of Pro/
Pro genotype as compared with the control group
(χ2= 7,0, p < 0,05 ), while a reliable difference bet-
ween the frequencies of Pro/Leu and Leu/Leu
genotypes in the main and control groups (χ2 = 1,9, p
>0,05 and χ2 = 2,6, p > 0,05) has not been found out.
It has been revealed that Pro/Leu and Leu/Leu
variants of polymorphism are associated with
increased risk of violation of redox system in patients
with MS  as compared with a group of healthy
subjects (table 1). Assessment of the relative risk
was carried by odds ratio (OR) magnitude. The OR
calculation showed that in patients with Pro/Leu
polymorphism the risk of disturbance of GPX 1
activity increases 5,2 times (p < 0,05, OR = 1,65, CI
= 0,95% 0,94 - 2,90), and in patients with Leu/Leu
genotype the risk of such patology is 6,0 times higher
than in persons with Pro/Pro genotype (P < 0,05, OR
= 1,92, CI 0,95% = 0,93 - 3,97).
So, the risk of GPX 1 activity reduction in a dose-
Table 1
The distribution of genotype frequencies depending on Pro197Leu polymorphism of GPX 1
gene in patients with metabolic syndrome and the control group
 
Cases Controls 
Genotypes 
102 97 
χ
2
 р OR 0,95% CI 
Genotype 
frequency 
Pro/ Pro 
0,176 0,402 0,32 0,17-0,61 
Genotype 
frequency 
Pro/Leu 
0,578 0,454 1,65 0,94-2,90 
Genotype 
frequency 
Leu /Leu 
0,245 0,144 
12,91 0,002 
1,92 0,93-3,97 
Note: χ
2
 - Pearson criterion, OR - odds ratio, CI - confidence interval. 
dependent way is associated with the presence of
"mutant" Leu-allele, while homozygous for the "wild"
Pro-allele had significantly lower risk of this
disturbance development. Pro allele has protective
properties concerning the development of redox
system violation.
When studying the dependence of functional state
of the endothelium on Pro197Leu  polymorphism of
GPX 1 gene, a significantly higher level of VEGF in
homozygous group for mutant Leu-allele and hetero-
zygous group for this allele in comparison with
homozygous ones for wild allele has been received,
45,3% and 62,8%  higher respectively  (p<0,05)
(table 2). A credible growth of VEGF in patients with
Pro/Pro, Pro/Leu and Leu/Leu genotypes in relation
to the group of healthy individuals was found 1,9, 2,8
and 3,2 times higher (p<0,05).
VEGF is a cytokine, expression of which inc-
reases during hypoxia, hyperglycemia, it is activated
in response to proinflammatory cytokines hyperp-
7roduction [7].
In our investigation VEGF expression increases,
probably due to transcription factors activation as a
cause of free radicals accumulation against a back-
ground of reduced GPX 1 activity. Free radicals start
the process of proinflammatory cytokines release by
activation of transcription factors such as NF-kb [8].
The number of circulating desquamated endo-
thelial cells was established to be 7,9% higher in the
group with Leu/Leu genotype as compared with the
group whith Pro/Pro genotype (p<0,05) and respec-
tively 3,4, 4,6 and 6,1 times higher in the groups with
Pro/Pro, Pro/Leu and Leu/Leu genotypes in com-
parison with the control group (p < 0,05). Small
desquamation of endothelial cells also took place in
the control group, which reflected the physiological
process of intimal clearance from dead cells [1].
The reason for the increased endothelium
desquamation intensity is probably due to lipid
peroxidation activation and increased cytokines exp-
ression, caused by accumulation of free radicals,
which is more pronounced in homozygous for the
"mutant" Leu-allele [4, 6, 8].
Thus, our data coincide with the results of other
researchers. Bastaki M. et al. have discovered that
GPX 1 activity 6 times slows down in homozygous
patients for the Leu-allele [4]. Association of
endothelial dysfunction with Pro197Leu polymor-
phism of GPX 1 gene is reflected in the Zelkova
T.V. et al. study. They found out that the homozygous
for mutant Leu-allele more often suffered from
coronary artery disease and myocardial infarction at
the age of until 50 years old [12].
Conclusion
1. In patients with metabolic syndrome the risk of
reduction of glutathione peroxidase 1 activity is
associated in a dose-dependent manner with the
presence of "mutant" Leu-allele, while homozygous
for the "wild" Pro-allele had a significantly lower risk
of this disorder.
2. The presence of Leu-allele in genotype of
patients with metabolic syndrome is associated with
functional state of the endothelium violation which is
probably due to the decreased GPX 1 activity.
Prospects for further research
The survey results indicate the necessity of effec-
tive measures for endothelial dysfunction correction
development in patients with metabolic syndrome.
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Table 2
Peculitaries of functional state of endothelium indicators in patients with metabolic
syndrome according to Pro197Leu polymorphism of the GPX 1 gene
 
Genotypes GPX 1 , n=102 Index 
Pro/Pro 
n=18 
Pro/Leu 
n=59 
Leu/Leu 
n=25 
Control group,  
n=20 
VEGF, pg / ml 146,3±16,83 
*/**/*** 
212,6±24,38 
* 
238,2±24,73 
* 
76,6±12,70 
 Endotheliocytes 
(10
4
/l) 
10,22±1,238 
*/*** 
13,8±2,214 
* 
18,25±2,964 
* 
2,99±0,423  
Notes: 1. n - number of observations; 2. * - the probability of changes in relation to control; 3.  **- the 
probability of changes in relation to the group with Pro/Leu-genotype; 4. ***- chance changes in relation to 
group with Leu/Leu genotype 
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ÂËÈßÍÈÅ PRO197LEU ÏÎËÈÌÎÐÔÈÇÌÀ ÃÅÍÀ GPX
1 ÍÀ ÏÎÊÀÇÀÒÅËÈ ÔÓÍÊÖÈÎÍÀËÜÍÎÃÎ
ÑÎÑÒÎßÍÈß ÝÍÄÎÒÅËÈß Ó ÁÎËÜÍÛÕ Ñ
ÌÅÒÀÁÎËÈ×ÅÑÊÈÌ ÑÈÍÄÐÎÌÎÌ
Í.Î. Àáðàìîâà, Í.Â. Ïàøêîâñêàÿ
Ðåçþìå. Íàìè èññëåäîâàíî Pro197Leu ïîëèìîðôèçì
ãåíà GPX 1 ó 102 ïàöèåíòîâ ñ ìåòàáîëè÷åñêèì ñèíäðîìîì è
97 ïðàêòè÷åñêè çäîðîâûõ ëèö. Â îñíîâíîé ãðóïïå âûÿâëåíû
íàðóøåíèÿ ðàñïðåäåëåíèÿ ÷àñòîò ãåíîòèïîâ ïî ñðàâíåíèþ ñ
ãðóïïîé êîíòðîëÿ çà ñ÷åò ñíèæåíèÿ ÷àñòîòû Pro/Pro ãåíî-
òèïà (ð<0,05). Ïðè àíàëèçå ïîëó÷åííûõ äàííûõ ìû
îáíàðóæèëè óâåëè÷åíèå ðèñêà íàðóøåíèÿ àêòèâíîñòè GPX
1 ó ëèö ñ Pro/Leu è Leu/Leu âàðèàíòàìè ïîëèìîðôèçìà ïî
ñðàâíåíèþ ñ ãîìîçèãîòàìè ïî "äèêîìó" àëëåëþ â 4,7 è 6,9
ðàçà ñîîòâåòñòâåííî (ð<0,05). Ó ïàöèåíòîâ ñ Leu/Leu ãåíî-
òèïîì äîñòîâåðíî âîçðàñòàëà ýêñïðåññèÿ ñîñóäèñòîãî
ýíäîòåëèàëüíîãî ôàêòîðà ðîñòà è èíòåíñèâíîñòü äåñê-
âàìàöèè ýíäîòåëèîöèòîâ ïî ñðàâíåíèþ ñ ãîìîçèãîòàìè ïî
"äèêèìó" Pro-àëëåëþ.
Èòàê, Pro-àëëåëü îáëàäàåò ïðîòåêòîðíûìè ñâîéñòâàìè,
ïðåïÿòñòâóÿ ñíèæåíèþ àêòèâíîñòè ãëóòàòèîíïåðîêñèäàçû. Ó
íîñèòåëåé Leu-àëëåëÿ, íà ôîíå ñíèæåíèÿ àêòèâíîñòè GPX 1,
ïðîèñõîäèò íàêîïëåíèå ñâîáîäíûõ ðàäèêàëîâ, ÿâëÿþùèõñÿ
ïðè÷èíîé ïåðåêèñíîãî îêèñëåíèÿ ëèïèäîâ è àêòèâàöèè
ôàêòîðîâ òðàíñêðèïöèè ñ ïîñëåäóþùèì ðîñòîì ýêñïðåññèè
öèòîêèíîâ, êîòîðûå òàêæå íåïîñðåäñòâåííî ïîðàæàþò
ýíäîòåëèé.
Êëþ÷åâûå ñëîâà: Pro197Leu ïîëèìîðôèçì ãåíà GPX 1,
ôóíêöèîíàëüíîå ñîñòîÿíèå ýíäîòåëèÿ, ñîñóäèñòûé ýíäî-
òåëèàëüíûé ôàêòîð ðîñòà, ýíäîòåëèîöèòû, ìåòàáîëè÷åñêèé
ñèíäðîì.
___________
ÂÏËÈÂ PRO197LEU ÏÎË²ÌÎÐÔ²ÇÌÓ ÃÅÍÀ GPX 1
ÍÀ ÏÎÊÀÇÍÈÊÈ ÔÓÍÊÖ²ÎÍÀËÜÍÎÃÎ ÑÒÀÍÓ
ÅÍÄÎÒÅË²Þ Ó ÕÂÎÐÈÕ ²Ç ÌÅÒÀÁÎË²×ÍÈÌ
ÑÈÍÄÐÎÌÎÌ
Í.Î. Àáðàìîâà, Í.Â. Ïàøêîâñüêà
Ðåçþìå. Íàìè äîñë³äæåíî Pro197Leu ïîë³ìîðô³çì ãåíó
GPX 1 ó 102 õâîðèõ ³ç ìåòàáîë³÷íèì ñèíäðîìîì òà 97
ïðàêòè÷íî çäîðîâèõ îñ³á. Â îñíîâí³é ãðóï³ âèÿâëåíî
ïîðóøåííÿ ðîçïîä³ëó ÷àñòîò ãåíîòèï³â ïîð³âíÿíî ³ç
ãðóïîþ êîíòðîëþ çà ðàõóíîê çíèæåííÿ ÷àñòîòè Pro/Pro
ãåíîòèïó (ð<0,05). Ïðè àíàë³ç³ îòðèìàíèõ äàíèõ ìè âèÿâèëè
çðîñòàííÿ ðèçèêó ïîðóøåííÿ àêòèâíîñò³ GPX 1 ó îñ³á ³ç
Pro/Leu òà Leu/Leu âàð³àíòàìè ïîë³ìîðô³çìó ïîð³âíÿíî ³ç
ãîìîçèãîòàìè çà "äèêèì" àëåëåì ó 4,7 òà 6,9 ðàçà (ð<0,05).
Ó îñ³á ³ç Leu/Leu ãåíîòèïîì â³ðîã³äíî çðîñòàëà åêñïðåñ³ÿ
ñóäèííîãî åíäîòåë³àëüíîãî ôàêòîðó ðîñòó òà ³íòåíñèâí³ñòü
äåñêâàìàö³¿ åíäîòåë³îöèò³â ïîð³âíÿíî ³ç ãîìîçèãîòàìè çà
"äèêèì" Pro-àëåëåì.
Îòæå, Pro-àëåëü âîëîä³º ïðîòåêòîðíèìè âëàñòèâîñòÿìè
ùîäî çíèæåííÿ àêòèâíîñò³ ãëóòàò³îíïåðîêñèäàçè. Ó íîñ³¿â
Leu-àëåëþ, íà òë³ çíèæåííÿ àêòèâíîñò³ GPX 1, â³äáóâàºòüñÿ
íàêîïè÷åííÿ â³ëüíèõ ðàäèêàë³â, ùî º ïðè÷èíîþ ïåðîê-
ñèäíîãî îêèñíåííÿ ë³ï³ä³â òà àêòèâàö³¿ ôàêòîð³â òðàíñêðèïö³¿
³ç íàñòóïíèì çðîñòàííÿì åêñïðåñ³¿ öèòîê³í³â, ÿê³ òàêîæ
áåçïîñåðåäíüî âðàæàþòü åíäîòåë³é.
Êëþ÷îâ³ ñëîâà: Pro197Leu ïîë³ìîðô³çì ãåíà GPX 1,
ôóíêö³îíàëüíèé ñòàí åíäîòåë³þ, ñóäèííèé åíäîòåë³àëüíèé
ôàêòîð ðîñòó, åíäîòåë³îöèòè, ìåòàáîë³÷íèé ñèíäðîì.
Áóêîâèíñüêèé äåðæàâíèé ìåäè÷íèé óí³âåðñèòåò
 (ì. ×åðí³âö³).
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